-
Horizon Therapeutics (HZNP) PT Raised to $118 at BMO Capital
-
Horizon Therapeutics (HZNP) PT Raised to $115 at BMO Capital
-
Horizon Therapeutics (HZNP) Tepezza Shortage 'Seems Manageable' - BMO
-
Horizon Therapeutics (HZNP) PT Raised to $110 at BMO Capital, Following Earnings
-
Horizon Pharma (HZNP) PT Raised to $40 and Highlighted as Top Pick at BMO Capital After TED AdComm
-
BMO Capital Upgrades Horizon Pharma (HZNP) to Outperform
-
Horizon Pharma (HZNP) PT Raised to $29 at BMO Capital
-
Horizon Pharma (HZNP) PT Raised to $21 at BMO Capital
-
Horizon Pharma (HZNP) PT Raised to $19 at BMO Capital
-
BMO Capital Downgrades Horizon Pharma (HZNP) to Market Perform
-
Horizon Pharma (HZNP) PT Raised to $18 at BMO Capital on 2Q Beat; 'Nice Reovery in 2Q... Raised Guidance Appears Conservative'
-
Horizon Pharma (HZNP) PT Lowered to $17 at BMO Capital; '1Q Primary Care Disappointment Overshadows Orphan Progress'
-
BMO Capital Reiterates Outperform Rating and $24 PT on Horizon Pharma (HZNP) Following Mgmt Meetings
-
Horizon Pharma (HZNP) PT Lowered to $24 at BMO Capital on FA Miss; Maintains 'Outperform'
-
BMO Sees Favorable Risk/Reward for Horizon Pharma (HZNP) Ahead of phase 3 Data for Actimmune in FA
-
Complete Donald Trump Stock Impact Guide
-
BMO Capital Reiterates Outperform on Horizon Pharma (HZNP) Following Announced RPTP Deal
-
Horizon Pharma (HZNP) PT Bumped to $30 at BMO Capital Amid 'Very Solid' Q2
-
BMO Capital Positive on Horizon Pharma (HZNP) Amid CVS/Caremark News; Affirms at 'Outperform'
-
BMO Capital Starts Horizon Pharma (HZNP) at Outperform
-
Pre-Open Stock Movers 04/12: (FOLD) (ARNA) (HLX) Higher; (HZNP) (OZM) (JNPR) Lower (more...)
-
Notable Analyst Rating Changes 11/23: (CMG) (JRVR) (PBF) Upgraded; (TXTR) (CTCT) (CAVM) Downgraded
-
Valeant vows to refute 'phantom sales' allegations
-
Notable Mergers and Acquisitions 7/7: (HZNP)/(DEPO) (LGCY) (MR) (DNN)
-
Pre-Open Stock Movers 4/14: (DOVR) (BCLI) (JPM) Higher; (RXII) (ARWR) (NSC) Lower (more...)

